RxDoctor Payments Data

Helene Muhirwa

Psychiatric/Mental Health · Columbus, OHNPI 1821530833

Payments from drug & device makers

$3,272in general payments, 2019–2025

Across 169 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$987
  • Axsome Therapeutics, Inc.$293
  • Indivior Inc.$172
  • Otsuka America Pharmaceutical, Inc.$170
  • Johnson & Johnson$159
  • plus $302 from 7 others

What the payments were for

  • Food & beverage$3,272100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,272 in reported general payments places this provider in the 80th percentile of 1,808 psychiatric/mental health providers in Ohio.

See all psychiatric/mental health providers in Ohio

Medicare billing

Part B allowed, 2024
$9,588
Medicare patients
29
Services billed
106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl48$73,451
Abilify MaintenaAripiprazole15$43,667
RexultiBrexpiprazole13$16,496
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl105$15,324
SuboxoneBuprenorphine Hcl/Naloxone Hcl20$10,388
Paliperidone ErPaliperidone24$5,731
VyvanseLisdexamfetamine Dimesylate14$5,497
Lurasidone Hcl41$3,948
Duloxetine Hcl82$3,047
Aripiprazole49$2,625
Quetiapine Fumarate140$1,954
Atomoxetine Hcl12$1,827
Divalproex Sodium20$1,531
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine15$1,517
Divalproex Sodium ErDivalproex Sodium20$1,310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,188$73,45148 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$170$60,16428 claims
Indivior Inc.Suboxone$172$10,38820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,808 psychiatric/mental health providers in Ohio.

Other psychiatric/mental health in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →